日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Utilization of extended-interval, fixed-dosing of durvalumab, every 4 weeks, in U.S. patients with unresectable stage III NSCLC following concurrent chemoradiation

在美国，对于接受同步放化疗后不可切除的 III 期非小细胞肺癌患者，采用每 4 周一次的固定剂量、延长间隔的度伐利尤单抗治疗。

期刊:Future Oncology
影响因子:2.6
doi:10.1080/14796694.2025.2603465
Haque, Reina; McGary, Eric; Yang, Mike Z; Liu, Raymond; Suga, J Marie; Chen, LieHong; Zhu, Zheng; Simmons, Daniel J; Hsieh, Kristin; Cotarla, Ion; Sakoda, Lori C
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Validation of an Administrative Claims-based Line of Therapy Algorithm for Women with Ovarian Cancer Using Medical Chart Review

利用病历审查验证基于行政索赔数据的卵巢癌女性治疗方案选择算法

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-025-03174-y
Simmons, Daniel; White, John; Walker, Valery; Blank, Stephanie V; Munley, Jiefen; McLaurin, Kimmie
肿瘤
肿瘤免疫
卵巢癌
发表日期：2025
文献求助 收藏

Incidence and Costs of Clinically Significant Events with Systemic Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study

不可切除肝细胞癌患者接受全身治疗后发生临床显著事件的发生率和成本：一项回顾性队列研究

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-024-02790-4
Simmons, Daniel J; Valerio, Stephen J; Thomas, Darren S; Healey, Marcus J; Jiang, Zhuoxin; Levingston Mac Leod, Jesica M; Lin, Yian; Sah, Janvi
细胞生物学
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Polarized Perceptions: How Time and Vaccination Status Modify Republican and Democratic COVID-19 Risk Perceptions

两极分化的认知：时间和疫苗接种状况如何影响共和党人和民主党人对新冠病毒风险的认知

期刊:Journal of Elections Public Opinion and Parties
影响因子:1.6
doi:10.1080/17457289.2023.2216461
Sandlin, Evan W; Simmons, Daniel J
微生物学
新冠
神经科学
发表日期：2024
文献求助 收藏

Durvalumab Treatment Patterns for Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Veterans Health Administration (VHA): A Nationwide, Real-World Study

退伍军人健康管理局 (VHA) 中不可切除的 III 期非小细胞肺癌患者的度伐利尤单抗治疗模式：一项全国性的真实世界研究

期刊:Current Oncology
影响因子:3.4
doi:10.3390/curroncol30090611
Moore, Amanda M; Nooruddin, Zohra; Reveles, Kelly R; Datta, Paromita; Whitehead, Jennifer M; Franklin, Kathleen; Alkadimi, Munaf; Williams, Madison H; Williams, Ryan A; Smith, Sarah; Reichelderfer, Renee; Cotarla, Ion; Brannman, Lance; Frankart, Andrew; Mulrooney, Tiernan; Hsieh, Kristin; Simmons, Daniel J; Jones, Xavier; Frei, Christopher R
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏

Health Care Resource Utilization and Costs Associated with Disease Progression in Ovarian Cancer

卵巢癌疾病进展相关的医疗资源利用和成本

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-022-02086-5
Simmons, Daniel; Blank, Stephanie V; ElNaggar, Adam C; Chastek, Benjamin; Bunner, Scott H; McLaurin, Kimmie
肿瘤
肿瘤免疫
卵巢癌
发表日期：2022
文献求助 收藏

Assessing the effectiveness of COVID-19 vaccine lotteries: A cross-state synthetic control methods approach

评估新冠疫苗抽签的有效性：一种跨州合成控制方法

期刊:PLoS One
影响因子:2.6
doi:10.1371/journal.pone.0274374
Fuller, Sam; Kazemian, Sara; Algara, Carlos; Simmons, Daniel J
微生物学
新冠
发表日期：2022
文献求助 收藏

Robust, Automated Analysis of Electrophysiology in Induced Pluripotent Stem Cell-Derived Micro-Heart Muscle for Drug Toxicity.

对诱导多能干细胞衍生的微型心肌进行稳健、自动化的电生理分析，以评估药物毒性

期刊:Tissue Engineering Part C-Methods
影响因子:2.6
doi:10.1089/ten.tec.2022.0053
Oguntuyo Kasoorelope, Schuftan David, Guo Jingxuan, Simmons Daniel, Bhagavan Druv, Moreno Jonathan D, Kang Po Wei, Miller Evan, Silva Jonathan R, Huebsch Nathaniel
发育与干细胞
细胞生物学
心肌炎
药物研究
发表日期：2022
文献求助 收藏

Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer

奥拉帕尼联合贝伐单抗与贝伐单抗单药治疗同源重组缺陷阳性晚期卵巢癌一线维持治疗的成本效益分析

期刊:Pharmacoeconomics-Open
影响因子:2.1
doi:10.1007/s41669-022-00338-2
Elsea, David; Fan, Lin; Mihai, Adela; Moustaid, Fadoua El; Simmons, Daniel; Monberg, Matthew; Muston, Dominic
卵巢癌
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏

Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer

更正：奥拉帕尼联合贝伐珠单抗与贝伐珠单抗单药治疗同源重组缺陷阳性晚期卵巢癌一线维持治疗的成本效益分析

期刊:Pharmacoeconomics-Open
影响因子:2.1
doi:10.1007/s41669-022-00372-0
Elsea, David; Fan, Lin; Mihai, Adela; Moustaid, Fadoua El; Simmons, Daniel; Monberg, Matthew; Muston, Dominic
卵巢癌
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏